| Study Name Sort descending | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| A022101 | The purpose of this study is to evaluate radiation, ablation and surgery. You must be diagnosed with metastatic colorectal cancer. The primary tumor must be able to surgically resected. | Cancer | Colorectal |
| A022102 | The purpose of this study is to compare effectiveness of mFOLFIRINOX with or without nivolumab and mFOLFOX6 with or without nivolumab . You must have newly diagnosed metastatic HER2 negative gastroesophageal cancer. | Cancer | Esophageal |
| A022104 | The purpose of this study is to look at the effectiveness of two chemo regimens mFOLFOX6 or CAPOX vs mFOLFIRINOX in getting patients to remission. You must be diagnosed with stage 2 or 3 rectal cancer. | Cancer | Rectal |
| A031701 | The purpose of this study is to compare standard or dose dense gemcitabine and cisplatin chemo. You must have been diagnosed with muscle invasive bladder cancer. | Cancer | Bladder |
| A031702 | The purpose of this study is to look at the effectineness of cabozantinib combined with nivolumab and ipilimubmab. You must be diagnosed with a rare genitourinary tumor of the kidney, bladder, ureters or penis. | Cancer | Rare Genitourinary |
| A031704 | The purpose of this study is to compare overall survival in patients treated with ipilimumab-nivolumab followed by either nivolumab or cabozantinib-nivolumab. You must be diagnosed with metastatic renal cell cancer. | Cancer | Metastatic Renal Cell |
| A031803 | The purpose of this study is to determine the effectiveness of intravesical gemcitabine in combination with prembrolizumab. Patients must have been diagnosed with invasive bladder and already received chemo. | Cancer | Bladder |
| A031902 | The purpose of this study is to evaluate progression free survival and overall survival with the use of enzalutamide and rucaparib vs enzalutamide alone. You must be diagnosed with metastatic castration-resistant prostate cancer. This must be your first treatment for your metastatic cancer. | Cancer | Metastatic Prostate |
| A032002 | The purpose of this study is to compare immunotherapy alone vs immunotherapy in combination with radiation for patients with metastatic Urothelial cancer. | Cancer | Metastatic Urothelial |
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| A081801 (sub study A151216) | The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A082002 | The purpose of this study is to determine in SBRT (stereotactic body radiation therapy) improves survival in advanced stage NSCLC. You must be diagnosed with stage 3 or 4 Non-Small Cell Lung Cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A151216 (ALCHEMIST) | The purpose of this study is to send tissue for screening of mutations to find targeted therapy for your cancer. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A212102 | This is a study looking at determining effectiveness of a multicancer early dectection blood test. Participants are healthy subjects, those with a known cancer diagnosis, and those with high suspicion of cancer. | Cancer | All tumor types |
| A221805 | This study is looking at using Duloxetine to prevent Oxaliplatin induced peripheral neuropathy. You must be diagnosed with stage 2 or 3 colorectal cancer scheduled to receive chemo with oxaliplatin. | Cancer | Colorectal |
| AALL08B1 | Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL0932 | Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL1231 | A Phase lll Randomized Trial Investigating Bortezomib (NSC#681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) | Childhood Cancers | Leukemia |
| AALL1521 | A Phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2 Rearranged and/ or JAK Pathway-Mutant Acute Lymphoblastic Leukemia | Childhood Cancers | Leukemia |
| Acoustic Diagnosis of Gastroesophageal Reflux Disease | Baby/Child | Reflux Disease | |
| Agendia FLEX | The purpose of this study is to create a large population based database to identify new gene associations in breast cancer. You must be diagnosed with stage 1, 2 or 3 breast cancer. A report is created that looks at the risk of your cancer spreading over the next 10 years. | Cancer | Breast |
| Amgen Ocean(a) | The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a). Patients must have a Lp(a) value of ≥ 200 nmol/L during screening. | Heart & Vascular | Cardiovascular Disease |
| Amplitude | This research study is a way to find out if the Study Drug is safe and if it works to help people with APOL-1 mediated Chronic Kidney Disease. | Nephrology | Proteinuric Kidney Disease |
| Amulet | Patients will have nonvalvular atrial fibrillation. This irregular beating of the heart leads to a slowing of the blood flow in the upper chambers of the heart. In the left upper chamber, there is a small pouch called the left atrial appendage (LAA). Slowing of blood, especially in the LAA, may cause blood clots to form. Blood clots can move from the LAA and travel to the brain, causing a stroke or transient ischemic attack (TIA), also called a mini-stroke. These blood clots can also travel to other parts of the body and block blood vessels. The Amulet device could be beneficial because it may lower the chance of a new blood clot forming and moving from the heart’s LAA to other parts of your body. | Heart & Vascular | Structural Heart Disease |
| ANBL1232 | Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma | Childhood Cancers | Blastoma |
| ANT-010/Lilac | A study to evaluate the effect of the experimental drug abelacimab relative to placebo in subjects with atrial fibrillation/flutter (AF) who are not treated with oral anticoagulants because they have been deemed by their responsible physicians or by their own decision to be unsuitable for currently available oral blood thinners. | Heart & Vascular | Atrial Fibrillation |
| APEC14B1 EveryChild | A Registry, Eligibility Screening, Biology and Outcome Study | Childhood Cancers | Registry |
| Arrhythmia Detection After Myocardial Infarction (AID-MI) | This study will evaluate the use of an insertable cardiac monitor in patients following an acute myocardial infarction (heart attack) to determine if cardiac monitoring results in more rhythm-related findings that change management compared to standard of care post heart attack management in patients who do not receive the insertable cardiac monitor. | Heart & Vascular | Cardiac Arrhythmia |
| Aveir DR | The objective for this study is to confirm the safety and effectiveness of the Aveir LP (Leadless Pacemaker) System in a subject population indicated for a dual chamber pacemaker. | Heart & Vascular | Cardiac Arrhythmia |
| Bayer ON-TRK | The purpose of this study is to learn about the effectiveness of Vitrakvi in patients with TRK Fusion cancer. You must have a advanced solid tumor with a NTRK gene fusion. | Cancer | All tumor types |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.